Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy

Toyoaki Hida,1 Kazuhiko Nakagawa,2 Takashi Seto,3 Miyako Satouchi,4 Makoto Nishio,5 Katsuyuki Hotta,6 Toshiaki Takahashi,7 Yuichiro Ohe,8,9 Koji Takeda,10 Masahiro Tatsuno,11 Takashi Asakawa,12 Tadashi Shimada,12 Tomohiro Tanaka12 and Tomohide Tamura8,13

1Department of Thoracic Oncology, Aichi Cancer Center, Nagoya; 2Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka; 3Department of Thoracic Oncology, National Kyusyu Cancer Center, Fukuoka; 4Department of Thoracic Oncology, Hyogo Cancer Center, Akashi; 5Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo; 6Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama; 7Department of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka; 8Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo; 9National Cancer Center East, Chiba; 10Department of Medical Oncology, Osaka City General Hospital, Osaka; 11Translational Clinical Research Science & Strategy Department, Chugai Pharmaceutical Co. Ltd., Tokyo; 12Clinical Science & Strategy Department, Chugai Pharmaceutical Co. Ltd., Tokyo; 13Thoracic Center, St. Luke’s International Hospital, Tokyo, Japan

Key words
Alectinib, anaplastic lymphoma kinase, bioequivalence, Japanese, non-small-cell lung cancer

Correspondence
Toyoaki Hida, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.
Tel: +81 52 762 6111; Fax: +81 52 759 3676;
E-mail: 107974@aichi-cc.jp

Funding Information
This work was supported by Chugai Pharmaceutical Co. Ltd. No grant number is applicable.

Clinical trial number
JapICIT-132186.

Accepted August 25, 2016; Revised August 22, 2016; Received May 26, 2016

Cancer Sci 107 (2016) 1642–1646
doi: 10.1111/cas.13066

We report pharmacokinetics, efficacy and safety data for a new 150-mg alectinib capsule in ALK+ non-small-cell lung cancer in a multicenter, open-label pharmacologic study (JP28927). Eligible patients (≥20 years, locally advanced/metastatic ALK+ disease, ALK inhibitor-naive and -pretreated [including crizotinib refractory]) were randomized 1:1 to receive one of two sequences of alectinib 300 mg twice daily (comprising different schedules of 20/40-mg and 150-mg capsules) until investigator-determined lack of clinical benefit. Co-primary endpoints were: bioequivalence of alectinib 20/40 mg vs 150 mg; food effect with 150 mg; and safety. Thirty-five patients were enrolled; median treatment duration was 13.1 months (range 1.1–15.0). Under fasting conditions, exposure of the two formulations was similar; mean AUClast ± standard deviation 3230 ± 914 h ng/mL vs 3710 ± 1040 h ng/mL, respectively, for 150-mg vs 20/40-mg capsules. Food effect with 150 mg alectinib was negligible. Treatment-related adverse events in >20% of patients were constipation (31.4%), dysgeusia (25.7%), and decreased white blood cell and neutrophil count (22.9% each). No treatment-related grade 4/5 events occurred. Median time to response was 1.2 months (95% CI 1.1–2.1). For the full analysis set (n = 35) and crizotinib-failure subpopulations (n = 23), the overall response rate was 70.0% (95% CI 50.6–85.3) and 65.0% (95% CI 40.8–84.6), and median progression-free survival was 13.9 months (95% CI 11.1–not reached) and 12.9 months (95% CI 3.9–not reached), respectively. The 150-mg capsule had a similar exposure profile to 20/40-mg capsules. Alectinib demonstrated promising efficacy and was well tolerated.

Lung cancer is the leading cause of cancer-related mortality worldwide.1 However, recent advances in knowledge of the molecular genotype of lung tumors have led to a revolution in the diagnosis and treatment of the disease. The anaplastic lymphoma kinase (ALK) gene is frequently involved in translocations that lead to gene fusions in a variety of malignancies, including lung cancer. It is estimated that ALK gene rearrangements occur in 4–5% of all patients with advanced non-small-cell lung cancer (NSCLC).2,3

Transforming rearrangements of the ALK gene were initially identified in anaplastic large-cell lymphoma.3 In 2007, a novel fusion oncogene that resulted in the expression of EML4–ALK fusion proteins was identified in NSCLC.4–6 ALK+ tumor cells displayed oncogenic behavior, being dependent on signaling from ALK fusion proteins for their survival.5,7 This observation formed the basis of targeting ALK as a therapeutic approach for the treatment of ALK+ NSCLC.

In 2011, the ALK inhibitor crizotinib was approved by the US Food and Drug Administration for the first-line treatment of advanced ALK+ NSCLC.8 Approval was partly based on a phase I study that reported an overall response rate (ORR) of 57% and a 6-month progression-free survival (PFS) rate of 72%.9 In 2014, ceritinib was granted accelerated approval in the USA for patients with ALK+ NSCLC who experienced disease progression (PD) or who were intolerant to crizotinib; approval was based on ORR of 58% (crizotinib naïve) and 56% (crizotinib pretreated) and a median PFS of 7.0 months.10

In 2014, alectinib, a central nervous system-penetrant and highly selective ALK inhibitor, was granted approval by the Japanese Ministry of Health, Labour and Welfare for the treatment of ALK+, unresectable, advanced or recurrent NSCLC in Japan. Approval was based on data from ALK inhibitor-naive patients with ALK+ NSCLC who received alectinib 300 mg
twice daily in a phase I/II study (AF-001JP). Alectinib was well tolerated and highly active, with >90% (43/46) of patients achieving an objective response.\(^{(11)}\) Follow-up is ongoing and, to date, 19.6% of patients have achieved a complete response (CR) and the 2-year PFS rate is 76%.\(^{(12,13)}\) Patients given alectinib in 20/40-mg capsules must take eight capsules to reach the recommended clinical dose of 300 mg.\(^{(11)}\) As this can be burdensome and could decrease compliance, we undertook the current study to demonstrate the bioequivalence of a new 150-mg capsule of alectinib vs the 20/40-mg capsules in patients with ALK+ NSCLC. We also investigated the safety and efficacy of alectinib in ALK+ NSCLC, including patients who had failed on crizotinib.

**Patients and Methods**

This multicenter, open-label, randomized study (JP28927) examined the bioequivalence and the effect of food on the bioavailability of 150-mg and 20/40-mg capsules of alectinib under fasting conditions in patients with ALK+ NSCLC (JapicCTI-132186).

Patients were randomly assigned using a permuted block randomization method in a 1:1 ratio to one of two groups to receive alectinib 300 mg twice daily in cycle 1 (30 days). The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The protocol was reviewed and approved by the institutional review boards of the participating institutions, and written informed consent was obtained from all patients.

**Treatment.** Patients in group A received alectinib 20/40-mg capsules for 10 days (fasting), followed by 150-mg capsules for 10 days (fasting), then 150-mg capsules for 10 days (non-fasting state) (Fig. S1). Patients in group B received alectinib 150-mg capsules for 10 days (fasting), followed by 20/40-mg capsules for 10 days (fasting), then 150-mg capsules for 10 days (non-fasting state). A washout period of 2 weeks was required between the last dose of crizotinib/prior ALK inhibitor and the first dose of alectinib. After cycle 1, patients received 150-mg alectinib capsules until investigator-determined lack of clinical benefit.

**Patients.** Eligible patients were aged ≥20 years, had histologically or cytologically confirmed advanced or metastatic ALK-rearranged, stage IIIIB/IV, or recurrent NSCLC, and an Eastern Cooperative Oncology Group performance status of 0–1. Prior treatment, including other ALK inhibitors, was allowed. Patients with meningeal or symptomatic brain metastases, or those who had received prior alectinib treatment, were excluded.

**Endpoints.** The primary endpoints were to evaluate: the bioequivalence of 300 mg twice-daily alectinib with 20/40-mg capsules vs 150-mg capsules under fasting conditions: the effect of food on the pharmacokinetics of alectinib after repeated oral administration of the 150-mg capsule after meals; and safety. Secondary endpoints included investigator-assessed ORR, PFS, time to response, duration of response and disease control rate (DCR). Efficacy and safety analyses were also undertaken in a subgroup of patients who had failed prior crizotinib.

**Assessments.** Blood samples for pharmacokinetic analysis were collected pre-dose and at 0.5, 1, 2, 4, 6, 8 and 10 h post-dose. Plasma alectinib concentrations were quantified using a liquid chromatography–mass spectrometry method with a lower limit of quantification of 0.10 ng/mL.\(^{(11)}\)

Tumor response and progression were assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at baseline, days 31 and 59, and then every 56 days. ORR was defined as the percentage of patients with a CR or partial response (PR) according to RECIST. Time to response was calculated from the first administration of alectinib until the date when the criteria for PR/CR were first met, with duration of response calculated from the date of first meeting the criteria for PR/CR until the date of confirmed PD/death, whichever occurred first. DCR comprised CR, PR and stable disease according to RECIST. PFS was calculated from the date of first administration of alectinib until the date of first PD or death, whichever occurred first. Adverse events (AE) were graded according to NCI-CTCAE version 4.03. The full analysis set (FAS) included all patients who were treated and eligible; all patients who received at least one dose of alectinib were included in the safety analysis population.

Anaplastic lymphoma kinase status was confirmed using FISH. A multiplex RT-PCR test was also carried out on cells or frozen tissue sections. Patients were deemed to be positive for ALK fusion gene expression when FISH and/or RT-PCR showed positive results.

**Statistical analysis.** Sample size was determined using the intra-individual variability of trough concentration data from the phase I/II parts of study AF-001JP\(^{(11)}\). The population pharmacokinetics model used in AF-001JP was also employed; the sample size, which had 80% power to detect bioequivalence in the area under the plasma concentration–time curve from time zero to the time of last alectinib concentration (AUC\(_{\text{last}}\)) and the maximum concentration (C\(_{\text{max}}\)), was estimated to be 30 patients.

Pharmacokinetic parameters for individual plasma concentration data were estimated using a non-compartmental method (Phoenix WinNonlin version 6.2; Certara, Cary, NC, USA); estimates and 90% confidence interval (CI) geometric mean ratios were derived from a mixed model (SAS version 9.2; SAS institute, Cary, NC, USA). Kaplan–Meier methodology was used to estimate the distribution of time to response, duration of response, and PFS. No formal comparisons were made between the FAS and crizotinib-failure populations.

Time to response, ORR, duration of response, and DCR were analyzed using data from patients who had measurable disease at baseline.

**Results**

Patients were enrolled between July and September 2013 (Fig. S2). Data are presented as of 6 November 2014 (the last patient’s last visit). Thirty-five patients with ALK+ NSCLC were recruited and randomly assigned to the two groups (Figs S1,S2); all were eligible for the FAS and safety populations. Twenty-nine patients (82.9%) had received at least one prior ALK inhibitor. Of 28 patients who had received previous crizotinib treatment, 23 were defined as crizotinib failures.

Median patient age was 45 years (range 21–78) for the FAS population and 43 years (range 21–64) for the crizotinib-failure population (Table 1). All patients had adenocarcinoma and most patients had received two or more prior chemotherapy regimens.

**Bioequivalence.** Under fasting conditions, exposure of the 150-mg alectinib capsule was similar to that of the 20/40-mg capsules; mean C\(_{\text{max}}\) ± SD, 390 ± 103 ng/mL vs 460 ± 122 ng/mL; AUC\(_{\text{last}}\) ± SD, 3230 ± 914 h·ng/mL vs 3710 ± 1040 h·ng/mL, respectively (Fig. S3a). The ratios of geometric mean were 0.868 (90% CI 0.801–0.941) for AUC\(_{\text{last}}\) and 0.846 (90% CI 0.784–0.913) for C\(_{\text{max}}\) for the 150-mg capsule
vs the 20/40-mg capsules (Table 2). Although the lower limit of the $C_{\text{max}}$ 90% CI was slightly below the criteria for bioequivalence (0.80–1.25), the AUC$_\text{last}$ met the criteria. *Food effect.* Exposure ($C_{\text{max}}$ and AUC$_\text{last}$) from the 150-mg capsule in the non-fasting state was approximately 20% higher than that in the fasting state, but this difference was within the interindividual variability range, and the effect of food on the pharmacokinetics of alectinib was considered negligible.

*Safety.* For patients taking the 20/40-mg and 150-mg capsules, all grade treatment-related AE occurring in >20% of patients were constipation (31.4%), dysgeusia (25.7%), and a decrease in white blood cell (WBC) (22.9%) and neutrophil cell count (22.9%) (Table 3). Grade 3 treatment-related AE were observed in three patients (pulmonary thrombosis, decrease in lymphocyte cell count, and hypophosphatemia). No treatment-related grade 4/5 AE were reported. Alectinib was interrupted or discontinued due to AE in 20% and 5.7% of patients, respectively. There were two cases of grade 1 interstitial lung disease including pneumonitis. Treatment-related nausea was experienced by 8.6% of patients in the safety population. In the crizotinib-failure population, all grade treatment-related AE reported in >20% of patients were constipation (30.4%), dysgeusia (30.4%), and a decrease in WBC count (21.7%).

**Table 1. Baseline characteristics of the full analysis set and the crizotinib-failure population**

| Characteristic              | FAS population | Crizotinib failure |
|-----------------------------|----------------|-------------------|
|                             | (n = 35)†      | (n = 23)‡         |
|                             | Number of patients | % | Number of patients | % |
| Age, years                  |                |                  |                |                  |
| Median                      | 45.0           | 43.0             |                |                  |
| Range                       | 21–78          | 21–64            |                |                  |
| Gender                      |                |                  |                |                  |
| Male                        | 16             | 45.7             | 10             | 43.5             |
| Female                      | 19             | 54.3             | 13             | 56.5             |
| ECOG PS                     |                |                  |                |                  |
| 0                           | 15             | 42.9             | 10             | 43.5             |
| 1                           | 20             | 57.1             | 13             | 56.5             |
| Smoking status              |                |                  |                |                  |
| Never                       | 21             | 60.0             | 15             | 65.2             |
| Current                     | 1              | 2.9              | 1              | 4.3              |
| Former                      | 13             | 37.1             | 7              | 30.4             |
| Adenocarcinoma              | 35             | 100.0            | 23             | 100.0            |
| Number of prior ALK inhibitors|              |                  |                |                  |
| 0                           | 6              | 17.1             | –              | –                |
| 1                           | 23             | 65.7             | 19             | 82.6             |
| 2                           | 6              | 17.1             | 4              | 17.4             |
| Number of prior chemotherapy regimens |          |                  |                |                  |
| 0–1                         | 6              | 17.1             | –              | –                |
| 2                           | 11             | 31.4             | 7              | 30.4             |
| ≥3                          | 18             | 51.4             | 16             | 69.6             |

†28/35 patients were crizotinib pretreated (of which, 5 patients also received ceritinib and 1 patient also received ASP3026); 1 patient received only ceritinib treatment. ‡Failure: patients experienced disease progression on crizotinib. §Including 3 patients who failed on ceritinib. ALK, anaplastic lymphoma kinase; ECOG PS, Eastern Cooperative Oncology Group performance status; FAS, full analysis set.

**Table 2. Bioequivalence analysis of 20/40-mg alectinib capsules vs the 150-mg capsule**

| PK parameter | Number of patients | Geometric LSM | Ratio of geometric LSM Estimate | 90% CI | Lower | Upper |
|--------------|--------------------|---------------|---------------------------------|--------|-------|-------|
|              | 20/40-mg capsule   | 150-mg capsule|                                 |        |       |       |
| AUC, h·ng/mL | 34                 | 3570          | 3100                            | 0.868  | 0.801 | 0.941 |
| $C_{\text{max}}$, ng/mL | 34                 | 445           | 377                             | 0.846  | 0.784 | 0.913 |

AUC, area under the curve; CI, confidence interval; $C_{\text{max}}$, maximum plasma concentration; LSM, least squares mean; PK, pharmacokinetics.

**Table 3. All-grade treatment-related adverse events in 10% or more of patients in the safety population and the crizotinib-failure population**

| Adverse event                  | Safety population | Crizotinib failure |
|--------------------------------|-------------------|-------------------|
|                                | (n = 35)†         | (n = 23)‡         |
|                                | Number | %     | Number | %    |
| Constipation                   | 11      | 31.4  | 7      | 30.4 |
| Dysgeusia                      | 9       | 25.7  | 7      | 30.4 |
| WBC count decreased            | 8       | 22.9  | 5      | 21.7 |
| Neutrophil count decreased     | 8       | 22.9  | 4      | 17.4 |
| Vomiting                       | 5       | 14.3  | 3      | 13.0 |
| Rash                           | 5       | 14.3  | 3      | 13.0 |
| Blood bilirubin increased      | 5       | 14.3  | 2      | 8.7  |
| AST increased                  | 5       | 14.3  | 1      | 4.3  |

†Treatment-related grade 3 adverse events were observed in 3 patients; pulmonary thrombosis (n = 1), decrease in lymphocyte cell count (n = 1), and hypophosphatemia (n = 1). Data are presented as of 6 November 2014, which was the last patient’s last visit. AST, aspartate aminotransferase; WBC, white blood cell.

**Table 4. Response rates with alectinib in the overall and crizotinib-failure populations**

| Response, n | Total (n = 30) | Crizotinib failure (n = 20) |
|-------------|----------------|-----------------------------|
| Complete response | 0 | 0  |
| Partial response | 21 | 13 |
| Stable disease | 4 | 3 |
| Progressive disease | 5 | 4 |
| ORR, % | 70.0 | 65.0 |
| 95% CI | 50.6–85.3 | 40.8–84.6 |
| DCR, % | 83.3 | 80.0 |
| 95% CI | 65.3–94.4 | 56.3–94.3 |
| Median time to response, months | 1.2 | 1.2 |
| 95% CI | 1.1–2.1 | 1.1–1.3 |

‡24/30 patients were crizotinib pretreated (of which, 4 patients also received ceritinib and 1 patient also received ASP3026); 1 patient received only ceritinib treatment. †Including 3 patients who failed on ceritinib. Data are presented as of 6 November 2014, which was the last patient’s last visit. CI, confidence interval; DCR, disease control rate; ORR, overall response rate.
70.0% (95% CI 50.6–85.3) and DCR was 83.3% (95% CI 65.3–94.4), with a median time to response of 1.2 months (95% CI 1.1–2.1). In the crizotinib-failure RE population (n = 20); ORR was 63.0% (95% CI 40.8–84.6) and DCR was 80.0% (95% CI 56.3–94.3) (Table 4); median time to response was 1.2 months (95% CI 1.1–1.3). Overall, 21 patients in the FAS RE population and 13 patients in the crizotinib-failure RE population had a PR; no patient achieved a CR. The median duration of response was not estimable in either the FAS or crizotinib-failure populations (range 2.5–14.1 months).

Median PFS was 13.9 months (95% CI 11.1–not reached [NR]) for all patients and 12.9 months (95% CI 3.9–NR) for the crizotinib-failure population (Fig. 1). A PFS event was observed in 14 patients who had experienced PD with crizotinib; no events occurred in patients who had discontinued crizotinib for reasons other than PD.

Discussion

Alectinib is approved by the Japanese Ministry of Health, Labour and Welfare for the treatment of ALK+ unresectable, advanced or recurrent NSCLC at a dose of 300 mg twice daily given in eight capsules (20/40 mg). In the present study, a new 150-mg alectinib capsule showed similar bioequivalence to the 20/40-mg capsules, and its food effect was negligible. These findings suggest that the 150-mg capsule could be a good substitute for eight 20/40-mg capsules, providing increased treatment administration choice for patients with ALK+ NSCLC.

Alectinib was well tolerated and had an acceptable safety profile with no treatment-related grade 4/5 AE or gastrointestinal toxicities leading to treatment withdrawal. These results are in line with the AF-001JP study and two phase II studies of alectinib in ALK+ NSCLC patients who had failed on crizotinib, despite the use of different alectinib doses. Although crizotinib is approved for the front-line treatment of ALK+ NSCLC, many patients who initially respond well undergo a relapse within 1 year of treatment. In this study, alectinib 300 mg twice daily showed favorable response rates in patients with ALK+ NSCLC, including those who had failed on prior crizotinib. These results are in line with phase I clinical studies in which alectinib led to tumor size reduction in models of crizotinib resistance. Even though the treatment dose was different, ORR in our study is also in agreement with data from the NP28761 study (ORR: 47.8%; DCR: 79.7%) and the NP28673 study (ORR: 50.0%; DCR: 78.7%). In addition, favorable median PFS of 13.9 and 12.9 months was observed in the FAS and crizotinib-failure populations, respectively, although these estimates could be unstable because of the distribution of censored patients. Our study is, however, limited by the small sample size and larger studies are required to validate the observed results.

This study demonstrated that a new 150-mg alectinib capsule has a similar pharmacokinetic profile to the existing 20/40-mg capsules, providing an additional therapeutic option for patients with ALK+ NSCLC. Furthermore, alectinib has promising efficacy and is well tolerated in patients with ALK+ NSCLC who have progressed on prior ALK inhibitors, including those with crizotinib-treatment history and crizotinib failures. It is of note that superior PFS with alectinib vs crizotinib has been recently demonstrated in a randomized phase III study of Japanese patients with ALK inhibitor-naïve, ALK+ NSCLC (J-ALEX; JapicCTI-132316). (20)

Acknowledgments

The authors would like to thank all participating physicians, registered patients, their families and Gardiner-Caldwell Communications for medical writing assistance. Medical writing assistance was funded by Chugai Pharmaceutical Co. Ltd.

Disclosure Statement

TH has received honoraria from Chugai Pharmaceutical Co. Ltd. and Pfizer, research funding from Chugai Pharmaceutical Co. Ltd., Pfizer and Novartis, and has acted in a consulting/advisory role to Novartis; KN has received honoraria and research funding from Chugai Pharmaceutical Co. Ltd. and Pfizer Japan Inc, and has participated in a speakers’ bureau for these companies; T Seto has received honoraria from Chugai Pharmaceutical Co. Ltd., Pfizer Japan Inc, and Novartis Pharma K.K.; and has received research funding from Chugai Pharmaceutical Co. Ltd., Pfizer Japan Inc., Novartis Pharma K.K. and Astellas Pharma Inc.; MS has received honoraria from Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical, Eli Lilly Japan, Pfizer, AstraZeneca, Novartis and Boehringer Ingelheim, and has received research funding from Chugai Pharmaceutical Co. Ltd., AstraZeneca, Novartis, Ono Pharmaceutical, Bristol-Myers Squibb, Eli Lilly Japan, Taiho Pharmaceutical, Pfizer Japan Inc., and MSD; MN has received honoraria from Pfizer, Chugai Pharmaceutical Co. Ltd., Eli Lilly, Taiho Pharmaceutical, Nichirei Biosciences, Elekta, AstraZeneca, Sanofi, Bristol-Myers Squibb and Ono Pharmaceutical, has acted in a consulting/advisory role to Novartis, Ono Pharmaceutical, Chugai Pharmaceutical Co. Ltd., Eli Lilly, Taiho Pharmaceutical, Daiichi Sankyo and Pfizer, and has received research funding from Novartis, Ono Pharmaceutical, Chugai Pharmaceutical Co. Ltd., Bristol-Myers Squibb Japan, Takeda Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Eli Lilly and Pfizer; KH has received honoraria from Chugai Pharmaceutical Co. Ltd., Eli Lilly, Taiho Pharmaceutical, Daiichi Sankyo and Pfizer, and has received research funding from Novartis, Ono Pharmaceutical, Chugai Pharmaceutical Co. Ltd., Bristol-Myers Squibb Japan, Takeda Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Eli Lilly and Pfizer; YO has received honoraria from Chugai Pharmaceutical Co. Ltd., AstraZeneca, Eli Lilly Japan K.K., Ono Pharmaceutical, and MS and Quintiles; YO has received honoraria from Chugai Pharmaceutical Co. Ltd., AstraZeneca, Eli Lilly, Pfizer, Ono Pharmaceutical, Daiichi Sankyo and Taiho Pharmaceutical, has acted in a consulting/advisory role to Chugai Pharmaceutical Co. Ltd., AstraZeneca, Eli Lilly and Boehringer Ingelheim, has received research funding from Chugai Pharmaceutical Co. Ltd., Ono Pharmaceutical, AstraZeneca, BMS, Eli Lilly, MSD and Novartis, has been paid to provide expert testimony for AstraZeneca, and has an immediate family member who is an employee of Chugai Pharmaceutical Co. Ltd.; KT has received honoraria from Chugai Pharmaceutical Co. Ltd.; MT, TA, T Shimada and T Tanaka are employees of Chugai Pharmaceutical Co. Ltd.; T Tamura has received honoraria from Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical, Eli Lilly, Ono Pharmaceutical, Eisai, Yakult, Boehringer Ingelheim and Bristol-Myers Squibb.

Original Article

Hida et al.

Cancer Sci | November 2016 | vol. 107 | no. 11 | 1645

© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
References

1. Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer, 2013. [Online; Cited 4 Aug 2016.] Available from URL: http://globocan.iarc.fr.

2. Chia PL, Mitchell P, Dobrovic A et al. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidermol 2014; 6: 423–32.

3. Morris SW, Kirstein MN, Valentine MB et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-hodgkin’s lymphoma. Science 1994; 263: 1281–4.

4. Hallberg B, Palmer RH. Mechanistic insight into the ALK receptor tyrosine kinase in human cancer biology. Nat Cancer Rev 2013; 13: 685–700.

5. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561–6.

6. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EMLA-ALK. J Clin Oncol 2009; 27: 4247–53.

7. Roskoski R Jr. Anaplastic lymphoma kinase (ALK): structure, oncogetic activation, and pharmacological inhibition. Pharmacol Res 2013; 68: 68–94.

8. National Comprehensive Cancer Network: Clinical Practice Guidelines for Non-small Cell Lung Cancer. V4.2016. [Online; Cited 4 Aug 2016.] Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

9. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibitor alectinib in ALK-rearranged non-small-cell lung cancer (NSCLC) US/Canadian population who had progressed on crizotinib (NP28761). J Clin Oncol 2015; 33 (15s): Abstract 8019.

10. Ou SH, Ahn JS, Petris L et al. Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) US/Canadian population who have failed prior crizotinib: an open-label, single-arm, global phase 2 study (NP28673). J Clin Oncol 2015; 33 (15s): Abstract 8008.

11. Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res 2014; 20: 2249–56.

12. Ou SH, Jänne PA, Bartlett CH et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014; 25: 415–22.

13. Kodama T, Tsukaguchi T, Yoshida M et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett 2014; 351: 215–21.

14. Nokihara H, Hida T, Kondo M et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+: NSCLC): primary results from the J-ALEX study. J Clin Oncol 2016; 34 (15s): Abstract 9008.

Supporting Information

Additional Supporting Information may be found online in the supporting information tab for this article:

Fig. S1. JP28927 study design.

Fig. S2. Trial profile of patient disposition.

Fig. S3. Pharmacokinetic assessment of (a) the bioequivalence of 20/40-mg capsules vs a 150-mg capsule of alectinib and (b) the effect of food on the 150-mg alectinib capsule.

Fig. S4. Treatment duration by individual patient (full analysis set).

Fig. S5. Maximum percentage change in tumor size from baseline (FAS response-evaluable population).